Chiesi to Acquire KalVista in $1.9B Rare Disease Deal
PARMA, ITALY & FRAMINGHAM, MASSACHUSETTS, April 29, 2026 Chiesi Group has announced a definitive agreement to acquire KalVista Pharmaceuticals...
Alzheimer’s Disease ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
PARMA, ITALY & FRAMINGHAM, MASSACHUSETTS, April 29, 2026 Chiesi Group has announced a definitive agreement to acquire KalVista Pharmaceuticals...
SOUTH SAN FRANCISCO, CALIFORNIA, April 30, 2026 IDEAYA Biosciences has announced that the U.S. Food and Drug Administration (FDA)...
South San Francisco, California, USA, April 21, 2026 In a significant advancement in precision oncology, IDEAYA Biosciences, Inc. has...
South San Francisco, California | April 10, 2026 IDEAYA Biosciences has announced that it will disclose topline results from...
San Diego, USA & Suzhou, China, April 2, 2026 Strong Clinical Efficacy in MSS Colorectal Cancer In a major...
South San Francisco, California, USA, April 6, 2026 First-in-Class Epigenetic Therapy Enters Clinical Development In a major step forward...
South San Francisco, California, USA | March 22, 2026 IDEAYA Biosciences has announced updated guidance on the anticipated topline...
